cancer drug — cancer drug — The Cyprus Oncology Society (OEK) has responded to growing concerns over delays in the approval of cancer treatment drugs by the Health Insurance Organisation (HIO). On Wednesday, OEK clarified its position amidst complaints from both healthcare professionals and patients regarding the accessibility of vital treatments.
Cancer drug: Understanding the Approval Process Changes
These delays have been attributed to procedural issues stemming from the transfer of the nominal requests committee from the Health Ministry to the HIO, a shift that occurred in May. This transition has raised questions about the efficiency of the approval process, prompting OEK to address these concerns directly.
Collaborative Efforts for Improvement
OEK has been actively involved in consultations aimed at refining and accelerating the approval process. A significant meeting on May 26 between OEK and HIO resulted in an agreement on a scientifically accepted timeline for updating and completing therapeutic protocols. This update has already led to a noticeable reduction in the number of nominal requests, indicating a potential streamlining of the process.
Rights of Treating Physicians and Patient Transparency
In its communication, OEK emphasised that when a request for treatment is rejected, treating physicians possess the right to appeal to a review board. This assurance aims to empower doctors in their efforts to secure necessary medications for their patients.
OEK reassured patients that the newly established criteria are being applied with transparency and seriousness. The Society remains committed to closely monitoring the progress of the drug approval system, indicating a readiness to intervene further if necessary.
Addressing Rising Complaints
The backdrop to OEK’s statements includes a series of complaints from oncologists and patients who have encountered obstacles in the approval process, often facing silence or rejections after submitting urgent requests for oncology drugs. The Society’s proactive stance highlights its concern for the wellbeing of patients awaiting critical treatments.
